Loxatias 25 Capsule contains Loxapine 25 mg, an antipsychotic agent primarily used in the management of schizophrenia and other psychotic disorders. Loxapine belongs to the class of dibenzoxazepine tricyclic antipsychotics and exerts its therapeutic effects by antagonizing dopamine D2 receptors in the central nervous system, thereby reducing psychotic symptoms such as hallucinations, delusions, and disorganized thinking. It also exhibits affinity for serotonin receptors, which may contribute to its efficacy and side effect profile. Loxatias 25 Capsule is indicated for the treatment of acute and chronic schizophrenia, helping to improve thought processes, mood, and behavior. The medication should be administered under strict medical supervision, with dosage tailored according to the patient’s clinical response and tolerability. Common adverse effects may include sedation, dizziness, dry mouth, and extrapyramidal symptoms such as tremors or rigidity. Caution is advised in patients with a history of cardiovascular disease, seizures, or hepatic impairment. Regular monitoring of clinical status and side effects is essential to ensure optimal therapeutic outcomes. Loxatias 25 Capsule should not be discontinued abruptly to avoid withdrawal symptoms or relapse. It is contraindicated in patients with known hypersensitivity to Loxapine or related compounds.